Developer docs
API playgroundTry for free, no card

Search company profiles

Salvia BioElectronics

Full company profile

uuid0000e5s

Namestring
Salvia BioElectronics
Legal namestring
Salvia BioElectronics B.V.
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Salvia BioElectronics B.V. is a clinical-stage medical device company founded in 2017 in Eindhoven, Netherlands, developing MySalvia Therapy, an implantable neuromodulation system for patients with resistant chronic migraine and chronic cluster headache. The therapy consists of two ultra-thin bioelectronic foil implants placed subcutaneously over the supra-orbital and occipital nerves, paired with an external wearable activator that delivers on-demand, patient-triggered electrical stimulation. The product has received FDA Breakthrough Device Designation and is the subject of the first FDA IDE-approved implantable neuromodulation pivotal trial in resistant migraine (RECLAIM), with parallel clinical studies (RELIEF, RESPONSE, RESPONSE-II) underway in the Netherlands, Belgium, and Australia, and a planned U.S. study.

The company targets a large underserved population: more than one billion people worldwide live with migraine, with resistant chronic migraine defined as persistent disability despite multiple preventive treatments. Cluster headache, the secondary indication, affects approximately 1 in 1,000 people and is treated as an orphan-class neurological condition. Salvia's go-to-market strategy is direct enterprise sales to headache specialists, neurologists, and hospital systems once regulatory approvals are obtained, with field sales leadership now being built out for the U.S. market under a newly appointed VP of U.S. Commercial Strategy and Operations.

Salvia has raised approximately €81 million in cumulative funding, including a $60 million (€53 million) oversubscribed Series B in May 2025 led by Innovation Industries with participation from Invest-NL, the EIC Fund, Inkef, Panakès Partners, SHS Capital, Thuja Capital, BOM, and Dolby Family Ventures. The company employs more than 70 people across 19 nationalities and is actively investing in an adjacent AI-driven closed-loop neurostimulation research initiative (CLUSTERSENSE) in partnership with Mentech Engineering and Leiden University Medical Center. As of the latest data, Salvia is pre-revenue, with all monetization contingent on regulatory approvals in the U.S., Europe, and Australia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersEindhoven, Netherlands
HQ citystring
Eindhoven
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuromodulation therapy, implantable neurostimulators, migraine medical devices, bioelectronic medicine, cluster headache treatment
Industry2 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKAIAM
Pain Medicine (Interventional/Neuropathic Pain)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Implantable Neuromodulation Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1MySalvia Therapy (Implant-based Neuromodulation)
TypeHardware Sales
Description

The company is developing an implantable neuromodulation therapy for chronic migraine and cluster headache. It is currently in clinical stage and not yet approved for commercial use. Revenue will be generated through product sales of the implant system and wearable device upon regulatory approval.

salviabioelectronics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Salvia BioElectronics is developing MySalvia Therapy, an investigational neuromodulation system for chronic migraine and cluster headache. The system consists of two ultra-thin implants placed beneath the skin at the supra-orbital and occipital nerve regions, paired with an external wearable device (MySalvia Device) that patients activate on demand by pressing a button to deliver targeted electrical stimulation to craniofacial nerves. The therapy is currently in clinical trials (RELAIM, RECLAIM, RESPONSE, RESPONSE-II) and is not yet approved for commercial use.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • MySalvia Therapy is being evaluated in clinical trials (RECLAIM, RELIEF, RESPONSE, RESPONSE-II) for safety and effectiveness in reducing migraine/cluster headache frequency and severity
Product overview1 text field

Salvia BioElectronics is a clinical-stage medical device company pioneering a single neuromodulation therapy — MySalvia Therapy — for people with resistant chronic migraine and cluster headache. MySalvia Therapy consists of two ultra-thin implantable neurostimulators (placed at the supraorbital and occipital nerve regions) paired with an external wearable device (MySalvia Device) that the patient activates on demand via button press to deliver targeted electrical stimulation. The therapy is designed to reduce migraine attack frequency and intensity by targeting key craniofacial nerves. It is currently investigational, evaluated across multiple clinical studies (RELIEF, RECLAIM, RESPONSE, RESPONSE-II) in Belgium, the Netherlands, Australia, and the United States, and is not yet approved for commercial use. The company is also exploring adaptive, data-informed use of its technology through the CLUSTERSENSE research initiative.

Product and service1 record
1MySalvia Therapy
CategoryImplantable Neuromodulation Therapy
Description

An implantable neuromodulation system for resistant chronic migraine and chronic cluster headache, consisting of two ultra-thin implants placed beneath the skin of the forehead and back of the head (at the supra-orbital and occipital nerve regions) plus an external wearable controller (MySalvia Device) that patients activate on demand to deliver targeted electrical stimulation to craniofacial nerves. Designed for patients who have failed multiple preventive treatments.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Collaboration in CLUSTERSENSE project (October 2025 - September 2028) developing AI-driven pain recognition system integrated with Salvia's neurostimulation technology. Mentech's HUME platform captures physiological signals for AI-based pattern recognition.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

CLUSTERSENSE project partner providing clinical expertise and access to well-characterized patient populations for validating AI models and translating results into clinical practice for cluster headache treatment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial site for RECLAIM migraine study in the Netherlands.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial site for RECLAIM migraine study in the Netherlands.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial site in Belgium, first in Europe to implant patients with Salvia's bioelectronic foil for severe migraine.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical trial site for RECLAIM migraine study in Belgium.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical trial site for RECLAIM migraine study in Belgium.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical trial site for RECLAIM migraine study in Belgium.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical trial site for RECLAIM migraine study in Belgium.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical trial site for RECLAIM migraine study in Belgium.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

electroCore markets gammaCore, a non-invasive vagus nerve stimulation (nVNS) therapy approved for migraine and cluster headache. Directly comparable as a neuromodulation therapy targeting the same primary indications as MySalvia, though delivered externally rather than via implants.

TypeDirect peer
Description

Theranica manufactures Nerivio, a wearable remote electrical neuromodulation (REN) device FDA-cleared for acute and preventive migraine. Direct competitor in the migraine neuromodulation space using a non-invasive wearable form factor versus Salvia's implantable approach.

TypeDirect peer
Description

Cefaly produces an external trigeminal nerve stimulation device FDA-cleared for migraine prevention. Competitor in transcutaneous supraorbital nerve stimulation for migraine, addressing the same nerve territory Salvia targets with its implant.

TypeDirect peer
Description

Nevro markets the HF10 high-frequency spinal cord stimulation system for chronic pain. Compares as a neuromodulation implantable device company targeting chronic pain, and Salvia's new VP U.S. Commercial came directly from Nevro's senior leadership.

TypeBroad incumbent
Description

Abbott's Neuromodulation division offers Proclaim XR, Proclaim DRG and other implantable neurostimulators for chronic pain and movement disorders. Broad incumbent in implantable neuromodulation with overlap in therapy category, channel (neurologists/pain physicians), and commercial model.

TypeBroad incumbent
Description

Medtronic offers Activa, Intellis, Vanta and other implantable neurostimulators across pain, DBS, and sacral neuromodulation. Large incumbent with adjacent technology, established clinical evidence in neuromodulation, and competing for the same hospital purchasing committees.

TypeBroad incumbent
Description

Boston Scientific markets Precision Spectra, WaveWriter Alpha and other SCS systems plus Vercise DBS. Comparable as an established implantable neuromodulation incumbent with broad indications, commercial reach, and R&D pipeline that could expand into migraine.

TypeBroad incumbent
Description

LivaNova offers VNS Therapy for epilepsy and depression via implantable pulse generators. Compares as an incumbent implantable neuromodulation company that has explored cranial nerve stimulation indications adjacent to Salvia's craniofacial approach.

TypeEmerging player
Description

Saluda Medical developed the Evoke closed-loop spinal cord stimulation system with objective neural response measurement. Comparable as a smaller neuromodulation player pursuing AI/closed-loop neurostim technology, similar in spirit to Salvia's CLUSTERSENSE adaptive initiative.

TypeEmerging player
Description

Mainstay Medical commercializes the ReActiv8 restorative neurostimulation system for chronic mechanical low back pain. Comparable as a clinical-to-commercial stage implantable neuromodulation company targeting chronic pain indications with a similar go-to-market profile.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Salvia BioElectronics

Implantable Neuromodulation Devicessalviabioelectronics.com

What Salvia BioElectronics does

Salvia BioElectronics B.V. is a clinical-stage medical device company founded in 2017 in Eindhoven, Netherlands, developing MySalvia Therapy, an implantable neuromodulation system for patients with resistant chronic migraine and chronic cluster headache. The therapy consists of two ultra-thin bioelectronic foil implants placed subcutaneously over the supra-orbital and occipital nerves, paired with an external wearable activator that delivers on-demand, patient-triggered electrical stimulation. The product has received FDA Breakthrough Device Designation and is the subject of the first FDA IDE-approved implantable neuromodulation pivotal trial in resistant migraine (RECLAIM), with parallel clinical studies (RELIEF, RESPONSE, RESPONSE-II) underway in the Netherlands, Belgium, and Australia, and a planned U.S. study.

The company targets a large underserved population: more than one billion people worldwide live with migraine, with resistant chronic migraine defined as persistent disability despite multiple preventive treatments. Cluster headache, the secondary indication, affects approximately 1 in 1,000 people and is treated as an orphan-class neurological condition. Salvia's go-to-market strategy is direct enterprise sales to headache specialists, neurologists, and hospital systems once regulatory approvals are obtained, with field sales leadership now being built out for the U.S. market under a newly appointed VP of U.S. Commercial Strategy and Operations.

Salvia has raised approximately €81 million in cumulative funding, including a $60 million (€53 million) oversubscribed Series B in May 2025 led by Innovation Industries with participation from Invest-NL, the EIC Fund, Inkef, Panakès Partners, SHS Capital, Thuja Capital, BOM, and Dolby Family Ventures. The company employs more than 70 people across 19 nationalities and is actively investing in an adjacent AI-driven closed-loop neurostimulation research initiative (CLUSTERSENSE) in partnership with Mentech Engineering and Leiden University Medical Center. As of the latest data, Salvia is pre-revenue, with all monetization contingent on regulatory approvals in the U.S., Europe, and Australia.

Salvia BioElectronics firmographics

Firmographics
Name
Salvia BioElectronics
Legal name
Salvia BioElectronics B.V.
Website
https://salviabioelectronics.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Salvia BioElectronics industry classification

Industry
Product category
Implantable Neuromodulation Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKAIAM
Pain Medicine (Interventional/Neuropathic Pain)

Keywords

  • Neuromodulation therapy
  • Implantable neurostimulators
  • Migraine medical devices
  • Bioelectronic medicine
  • Cluster headache treatment

Where Salvia BioElectronics is headquartered

Location

Headquarters

HQ city
Eindhoven
HQ country
Netherlands
HQ region
Europe

Offices2 records

Markets served

Salvia BioElectronics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. MySalvia Therapy (Implant-based Neuromodulation): The company is developing an implantable neuromodulation therapy for chronic migraine and cluster headache. It is currently in clinical stage and not yet approved for commercial use. Revenue will be generated through product sales of the implant system and wearable device upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Salvia BioElectronics product offering

Product offering

Core offering

Salvia BioElectronics is developing MySalvia Therapy, an investigational neuromodulation system for chronic migraine and cluster headache. The system consists of two ultra-thin implants placed beneath the skin at the supra-orbital and occipital nerve regions, paired with an external wearable device (MySalvia Device) that patients activate on demand by pressing a button to deliver targeted electrical stimulation to craniofacial nerves. The therapy is currently in clinical trials (RELAIM, RECLAIM, RESPONSE, RESPONSE-II) and is not yet approved for commercial use.

Product overview

Salvia BioElectronics is a clinical-stage medical device company pioneering a single neuromodulation therapy — MySalvia Therapy — for people with resistant chronic migraine and cluster headache. MySalvia Therapy consists of two ultra-thin implantable neurostimulators (placed at the supraorbital and occipital nerve regions) paired with an external wearable device (MySalvia Device) that the patient activates on demand via button press to deliver targeted electrical stimulation. The therapy is designed to reduce migraine attack frequency and intensity by targeting key craniofacial nerves. It is currently investigational, evaluated across multiple clinical studies (RELIEF, RECLAIM, RESPONSE, RESPONSE-II) in Belgium, the Netherlands, Australia, and the United States, and is not yet approved for commercial use. The company is also exploring adaptive, data-informed use of its technology through the CLUSTERSENSE research initiative.

Differentiator

Problem solved

Functional benefit

Products and services

  • MySalvia Therapy An implantable neuromodulation system for resistant chronic migraine and chronic cluster headache, consisting of two ultra-thin implants placed beneath the skin of the forehead and back of the head (at the supra-orbital and occipital nerve regions) plus an external wearable controller (MySalvia Device) that patients activate on demand to deliver targeted electrical stimulation to craniofacial nerves. Designed for patients who have failed multiple preventive treatments.

Quantifiable outcome

  • MySalvia Therapy is being evaluated in clinical trials (RECLAIM, RELIEF, RESPONSE, RESPONSE-II) for safety and effectiveness in reducing migraine/cluster headache frequency and severity

Companies that use Salvia BioElectronics

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Salvia BioElectronics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature4 records

Salvia BioElectronics partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and supporting.

  • Mentech EngineeringcoreStrategic or Co-development Partner · 1 October 2025Collaboration in CLUSTERSENSE project (October 2025 - September 2028) developing AI-driven pain recognition system integrated with Salvia's neurostimulation technology. Mentech's HUME platform captures physiological signals for AI-based pattern recognition.
  • Leiden University Medical Center (LUMC)coreStrategic or Co-development Partner · 1 October 2025CLUSTERSENSE project partner providing clinical expertise and access to well-characterized patient populations for validating AI models and translating results into clinical practice for cluster headache treatment.
  • Erasmus MC RotterdamcoreStrategic or Co-development PartnerClinical trial site for RECLAIM migraine study in the Netherlands.
  • St. Antonius Hospital NieuwegeincoreStrategic or Co-development PartnerClinical trial site for RECLAIM migraine study in the Netherlands.
  • AZ Delta RoeselarecoreStrategic or Co-development PartnerClinical trial site in Belgium, first in Europe to implant patients with Salvia's bioelectronic foil for severe migraine.
  • ZAS AntwerpsupportingStrategic or Co-development PartnerClinical trial site for RECLAIM migraine study in Belgium.
  • Jessa Hospital HasseltsupportingStrategic or Co-development PartnerClinical trial site for RECLAIM migraine study in Belgium.
  • AZ Sint-Jan BrugessupportingStrategic or Co-development PartnerClinical trial site for RECLAIM migraine study in Belgium.
  • AZ Groeninge KortrijksupportingStrategic or Co-development PartnerClinical trial site for RECLAIM migraine study in Belgium.
  • AZ OostendesupportingStrategic or Co-development PartnerClinical trial site for RECLAIM migraine study in Belgium.

Scale indicators7 records

Recent moves6 records

Expansion highlights7 records

Salvia BioElectronics competitors and assessment

Company assessment

Direct peers

  • electroCore: electroCore markets gammaCore, a non-invasive vagus nerve stimulation (nVNS) therapy approved for migraine and cluster headache. Directly comparable as a neuromodulation therapy targeting the same primary indications as MySalvia, though delivered externally rather than via implants.
  • Theranica Bio-Electronics: Theranica manufactures Nerivio, a wearable remote electrical neuromodulation (REN) device FDA-cleared for acute and preventive migraine. Direct competitor in the migraine neuromodulation space using a non-invasive wearable form factor versus Salvia's implantable approach.
  • Cefaly Technology: Cefaly produces an external trigeminal nerve stimulation device FDA-cleared for migraine prevention. Competitor in transcutaneous supraorbital nerve stimulation for migraine, addressing the same nerve territory Salvia targets with its implant.
  • Nevro: Nevro markets the HF10 high-frequency spinal cord stimulation system for chronic pain. Compares as a neuromodulation implantable device company targeting chronic pain, and Salvia's new VP U.S. Commercial came directly from Nevro's senior leadership.

Broad incumbents

  • Abbott (Neuromodulation): Abbott's Neuromodulation division offers Proclaim XR, Proclaim DRG and other implantable neurostimulators for chronic pain and movement disorders. Broad incumbent in implantable neuromodulation with overlap in therapy category, channel (neurologists/pain physicians), and commercial model.
  • Medtronic (Neuromodulation): Medtronic offers Activa, Intellis, Vanta and other implantable neurostimulators across pain, DBS, and sacral neuromodulation. Large incumbent with adjacent technology, established clinical evidence in neuromodulation, and competing for the same hospital purchasing committees.
  • Boston Scientific (Neuromodulation): Boston Scientific markets Precision Spectra, WaveWriter Alpha and other SCS systems plus Vercise DBS. Comparable as an established implantable neuromodulation incumbent with broad indications, commercial reach, and R&D pipeline that could expand into migraine.
  • LivaNova: LivaNova offers VNS Therapy for epilepsy and depression via implantable pulse generators. Compares as an incumbent implantable neuromodulation company that has explored cranial nerve stimulation indications adjacent to Salvia's craniofacial approach.

Emerging players

  • Saluda Medical: Saluda Medical developed the Evoke closed-loop spinal cord stimulation system with objective neural response measurement. Comparable as a smaller neuromodulation player pursuing AI/closed-loop neurostim technology, similar in spirit to Salvia's CLUSTERSENSE adaptive initiative.
  • Mainstay Medical: Mainstay Medical commercializes the ReActiv8 restorative neurostimulation system for chronic mechanical low back pain. Comparable as a clinical-to-commercial stage implantable neuromodulation company targeting chronic pain indications with a similar go-to-market profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Salvia BioElectronics social profiles

Digital presence

Salvia BioElectronics compliance and trust

Trust signal

Compliance2 records

Salvia BioElectronics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Salvia BioElectronics leadership team

Management profile

Number of profiles

Profiles14 records

Salvia BioElectronics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Salvia BioElectronics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Salvia BioElectronics

What does Salvia BioElectronics do?

Salvia BioElectronics is developing MySalvia Therapy, an investigational neuromodulation system for chronic migraine and cluster headache. The system consists of two ultra-thin implants placed beneath the skin at the supra-orbital and occipital nerve regions, paired with an external wearable device (MySalvia Device) that patients activate on demand by pressing a button to deliver targeted electrical stimulation to craniofacial nerves. The therapy is currently in clinical trials (RELAIM, RECLAIM, RESPONSE, RESPONSE-II) and is not yet approved for commercial use.

Is Salvia BioElectronics a public or private company?

Salvia BioElectronics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Salvia BioElectronics founded?

Salvia BioElectronics was founded in 2017. It employs 51 to 100 people.

Where is Salvia BioElectronics based?

Salvia BioElectronics is headquartered in Eindhoven, Netherlands, in the Europe region.

How does Salvia BioElectronics make money?

One revenue line is on record: mySalvia Therapy (Implant-based Neuromodulation).

Who are Salvia BioElectronics's main competitors?

Direct peers on record are electroCore, Theranica Bio-Electronics, Cefaly Technology and Nevro. Broad incumbents are Abbott (Neuromodulation), Medtronic (Neuromodulation), Boston Scientific (Neuromodulation) and LivaNova. Emerging players are Saluda Medical and Mainstay Medical.

Does Salvia BioElectronics have an API?

No public API is recorded for Salvia BioElectronics.

What industry is Salvia BioElectronics in?

Salvia BioElectronics's product category is Implantable Neuromodulation Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAKAIAM, Pain Medicine (Interventional/Neuropathic Pain). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
HuntscanlonCoulter Partners Places Seasoned U.S. MedTech Executive Jill Schiaparelli as Chair of the Board of Directors of Salvia BioElectronicsCoulter Partners successfully placed Jill Schiaparelli as Chair of the Board of Directors at Salvia BioElectronics, a clinical-stage medical device company pioneering MySalvia neuromodulation therapy for resistant migraine. The appointment reflects Salvia's strategic expansion of its U.S. leadership team as the company advances its investigational therapy through clinical evaluation toward commercialization in both the U.S. and EU markets. Schiaparelli brings nearly three decades of experience in medical devices and neuromodulation, including prior leadership roles at Avation Medical, AxoGen, and ApaTech, along with a track record of guiding companies through FDA clearance and market entry.IO+Brainport’s health ecosystem moves from startup success to scaleA Dealroom-based snapshot commissioned by the Gerard & Anton Foundation shows that Brainport Eindhoven hosts 47 active medtech and healthtech startups and scaleups that have collectively raised €611 million across 114 funding rounds, representing 32% of all post-2010 regional startups and 24% of all funding. Companies such as ONWARD Medical (€207M raised, FDA De Novo approval for spinal cord stimulation therapy) and Salvia BioElectronics (€81M) illustrate how the region's deep-tech strengths have produced internationally competitive ventures. New initiatives including the TU/e HEALTH Institute, CUREON, and the Smart BioMaterials Center aim to provide long-term infrastructure for clinical translation and scaling, addressing the ecosystem's historical gap between lab and market.VentureRadarNew Funding Rounds in neurostimulationThe article presents a curated list of recent venture funding rounds for multiple startups specializing in neurostimulation and neurotechnology. Key transactions include SetPoint Medical raising $140 million, Salvia BioElectronics securing $60 million, and Coherence Neuro obtaining $10 million to advance their respective therapies. The report highlights diverse applications ranging from cancer treatment and chronic pain management to sleep apnea and erectile dysfunction.SalviabioelectronicsSalvia BioElectronics secures $60M in oversubscribed Series B to bring its pioneering migraine therapy to marketSalvia BioElectronics has secured a $60 million oversubscribed Series B funding round to advance its MySalvia Therapy, a neuromodulation device for chronic migraine. The capital will support the completion of clinical development and commercial launch preparations in the United States, Europe, and Australia, alongside efforts to obtain FDA market authorization. Led by Innovation Industries with participation from several other investors, this financing marks a significant step toward bringing the therapy to patients after early data showed promise in reducing attack frequency.GlobeNewswireSalvia BioElectronics Secures $60M in Oversubscribed SeriesSalvia BioElectronics, a clinical-stage medical device company headquartered in Eindhoven, Netherlands, announced the successful completion of a $60 million (€53 million) Series B financing round led by Innovation Industries, with participation from Invest-NL, EIC Fund, and existing investors. The funds will support completion of clinical development and commercial launch preparations for MySalvia Therapy, a neuromodulation treatment for chronic migraine, across the United States, Europe, and Australia, including obtaining FDA market authorization and regulatory approvals. Salvia's therapy, currently evaluated in the RECLAIM study, targets key nerves involved in migraine through an ultra-thin implant designed to reduce attack frequency and intensity.Tech.euSalvia BioElectronics raises $60M to accelerate its migraine therapy launchSalvia BioElectronics closed a $60 million Series B round led by Innovation Industries to advance its MySalvia Therapy for chronic migraine. The funding will support the RECLAIM clinical trial and regulatory filings in the US, Europe, and Australia. The device holds FDA Breakthrough Device Designation.NL TimesFirst patient in the Netherlands receives innovative chronic migraine implantThe first patient in the Netherlands received an implant for chronic migraine at Erasmus MC in Rotterdam. The device, developed by Salvia BioElectronics, emits electrical pulses to nerves and is part of the RECLAIM study. Further research is needed to confirm long-term effectiveness and safety.PR NewswireSalvia BioElectronics: First-Ever Patient Treated with Breakthrough Neuromodulation Solution for Severe Migraine and Cluster Headache in AustraliaAn Australian patient at Nambour Selangor Private Hospital became the first-ever recipient of Salvia BioElectronics' paper-thin neuromodulation solution for severe migraine and cluster headache, marking the first implantation of bioelectronic foils globally. The 29-year-old patient, who has suffered debilitating headaches since age 14, experienced immediate improvements in the frequency and intensity of her cluster headache attacks following the procedure. This milestone represents a significant step in Salvia BioElectronics' clinical trial program, with the company founded in 2017 to develop flexible bioelectronic foils that conform to head anatomy for headache treatment.PR NewswireSalvia BioElectronics' Groundbreaking Neuromodulation Solution for Severe Migraine and Cluster Headaches Administered to First PatientSalvia BioElectronics announced the successful first implantation of their paper-thin neuromodulation solution for severe migraine and cluster headaches in a 29-year-old patient in Australia, marking the first time in medical history that bioelectronic foils were used to treat these conditions. The first patient experienced immediate improvements in the number and intensity of migraine and cluster headache attacks following the procedure. The company, which received FDA breakthrough medical device designation in 2020, is now building clinical evidence to support market launch of this therapy targeting an unmet medical need affecting one in seven people globally.PR NewswireSalvia BioElectronics appoints Dr Alan Levy as ChairmanSalvia BioElectronics B.V. has appointed Dr. Alan Levy as Chairman of its Board of Directors to leverage his extensive experience in the medical device industry. This leadership change positions the Dutch neurostimulation company to advance its development of bioelectronic therapies for chronic migraine during its next phase of growth.